BI 754111

DRUG5 trials

Conditions

Advanced TumorsCarcinoma, Non-Small-Cell LungHead and Neck NeoplasmsMetastatic Solid TumorsNeoplasm MetastasisNeoplasms

Early Phase 1

This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer

CompletedNCT03433898

Boehringer IngelheimNeoplasms

Start: 2018-02-23End: 2023-07-20Updated: 2025-12-19

Phase 1

This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.

CompletedNCT03156114

Boehringer IngelheimCarcinoma, Non-Small-Cell Lung, Neoplasms

Start: 2017-06-13End: 2023-06-06Updated: 2026-01-26

This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091

TerminatedNCT03780725

Boehringer IngelheimCarcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms

Start: 2019-01-22End: 2020-12-08Updated: 2026-01-13

A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)

CompletedNCT03964233

Boehringer IngelheimNeoplasms

Start: 2019-06-20End: 2026-02-06Updated: 2026-02-18

Phase 2

Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours

CompletedNCT03697304

Boehringer IngelheimAdvanced Tumors, Metastatic Solid Tumors, Neoplasm Metastasis

Start: 2019-03-19End: 2024-12-03Updated: 2026-01-27

Journal of Translational Medicine2024-10-142 citations

Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours

Cancer Immunology Immunotherapy2024-03-303 citations

Efficacy and safety of brigimadlin (BI 907828), an MDM2–p53 antagonist, in patients (pts) with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials.

Journal of Clinical Oncology2024-01-208 citations

<sup>89</sup>Zr-immuno-PET using the anti-LAG-3 tracer [<sup>89</sup>Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC.

2023-03-0224 citations

Efficacy and safety of the MDM2–p53 antagonist BI 907828 in patients with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials.

Journal of Clinical Oncology2023-01-249 citations

Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors

ESMO Open2022-09-1213 citations

Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses

OncoImmunology2022-06-1621 citations

A phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 (ezabenlimab) and BI 754111 in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2022-06-017 citations

Ezabenlimab (BI 754091), an anti-PD-1 antibody, in combination with BI 836880, a VEGF/Ang2-blocking nanobody, in patients (pts) with advanced colorectal cancer (CRC).

Journal of Clinical Oncology2022-01-19

Platform trial of ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients (pts) with previously treated advanced solid tumors: Combination with BI 836880, a VEGF/Ang2-blocking nanobody.

Journal of Clinical Oncology2021-05-202 citations

Phase I study of BI 754091 plus BI 754111 in Asian patients with gastric/gastroesophageal junction or esophageal cancer.

Journal of Clinical Oncology2021-01-207 citations

Platform trial of BI 754091, an anti-PD-1 antibody, in patients with previously treated advanced solid tumors: Combination with BI 836880, a VEGF/Ang2-blocking nanobody.

Journal of Clinical Oncology2021-01-202 citations

Abstract 779: A phase I study of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb: Biomarker analyses from the microsatellite stable metastatic colorectal cancer (MSS mCRC) cohort

Cancer Research2020-08-1510 citations

Safety of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb, in patients with advanced solid tumors.

Journal of Clinical Oncology2020-05-2013 citations

An open-label, phase I trial of BI 754091 alone and in combination with BI 754111 in Asian patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2020-05-202 citations

A phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 and BI 754111 in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2020-05-201 citations

Phase I study of BI 754111 (anti-LAG-3) plus BI 754091(anti-PD-1) in patients (pts) with advanced solid cancers, followed by expansion in pts with microsatellite stable metastatic colorectal cancer (mCRC), anti-PD-(L)1-pretreated non-small cell lung cancer (NSCLC) and other solid tumors

Annals of Oncology2018-10-014 citations

Abstract 4547: Characterization of the LAG-3 targeting antibody BI 754111 in monotherapy and in combination with the anti-PD-1 antibody BI 754091

Cancer Research2018-07-015 citations

BI 754111

Sponsors

Conditions

Early Phase 1

Phase 1

Phase 2

Related Papers